Cadrenal Therapeutics (CVKD) EBITDA (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted EBITDA of -$2.5 million for Q3 2024, little changed sequentially from -$2.5 million in Q2 2024, and down 115.3% YoY from $16.1 million in Q4 2023.
Cadrenal Therapeutics (CVKD) EBITDA (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported EBITDA for 3 years, with the latest figure at -$2.5 million in Q3 2024.
- Quarterly EBITDA fell 115.3% year-over-year to -$2.5 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$7.9 million (down 6.73% YoY) and the FY2023 annual result came in at -$7.6 million, down 182.53% from the prior year.
- EBITDA steadied at -$2.5 million in Q3 2024 per CVKD's latest filing, from -$2.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$170521.0 in Q1 2022 and troughed at -$4.2 million in Q1 2023.
- A 3-year average of -$1.5 million and a median of -$1.1 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA tumbled 2363.18% in 2023, then surged 58.2% in 2024.
- Over 3 years, EBITDA stood at -$1.1 million in 2022, then retreated by 17.46% to -$1.3 million in 2023, then tumbled by 94.64% to -$2.5 million in 2024.
- According to Business Quant data, EBITDA over the past three periods registered -$2.5 million, -$2.5 million, and -$1.8 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 133.12 Mn |
| 10 | Cadrenal Therapeutics | 4.69 Mn | 2.29 Mn | - | -3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.34 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Sep 30, 2024 | -2.46 Mn |
| Jun 30, 2024 | -2.47 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -1.14 Mn |
| Jun 30, 2023 | -1.03 Mn |
| Mar 31, 2023 | -4.20 Mn |
| Dec 31, 2022 | -1.08 Mn |
| Sep 30, 2022 | -972,791.00 |
| Jun 30, 2022 | -482,347.00 |
| Mar 31, 2022 | -170,521.00 |